Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three reviewers, whose comments are attached below. As you will see, all of them consider your structural and biochemical/biophysical insights on the PH-CC-Ex domain of Tiam1/2 interesting and potentially important for better understanding the functional significance of various protein-protein interactions mediated by this domain. At the same time, they nevertheless also raise a number of substantive concerns that would need to be satisfactorily addressed before publication in The EMBO Journal may be warranted. Some of these concerns pertain to aspects of interpretation, discussion and presentation, while others are more specific points regarding an extension of the in vitro interaction work. While not all of the latter may be equally important and useful for obtaining major additional insight (I am happy to discuss this further if you wish), an essential issue for successful revision would however be to follow referee 2's suggestion to exploit the in vitro insights for gaining further insights on the functional significance of PH-CC-Exmediated interactions in a cellular context. Specifically, this reviewer provides some rather concrete suggestions for Rac1 functional assays and/or co-IP experiments.
Should you be able to add such functional insights in the spirit of referee 2's comments, as well as to adequately respond to the various other points raised, then we should be able to consider a revised version of the manuscript for publication. I need to stress, however, that obtaining at least some conclusive insights in response to referee 2's main concern will be essential if you wish the manuscript ultimately to be accepted. Please also be reminded that it is EMBO Journal policy to allow a single round of major revision only, and that it is therefore essential that you diligently answer to all the points raised at this stage. In any case, please do not hesitate to get back to us should you need feedback on any issue regarding your revision.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The Rac-specific guanine nucleotide exchange factor Tiam1 was identified first in 1994 by in vitro selection for invasiveness in T-lymphoma cells. Now 15 years later, it belongs to the bestinvestigated GEFs has multiple roles in regulating cellular functions including cell adhesion, axonal and epithelial cell polarity, motility in neuronal cells and cellular migration. Structural and biochemical aspect of the GEF function of Tiam1 has been also characterized in detail. However, little is known about the molecular basis of Tiam1 integration at the plasma membrane by upstream signals. Now, above manuscript provides insight into this very important aspect. By determining the crystal structure of the PHCCEx they find out that CC and Ex subdomains from the binding site for Tiam1 interaction with CD44, Ephrin B, Par3 and JIP2. These subdomains provide a positivelycharged surface that is required to interact with acidic sequence motifs in these target proteins and stabilized by binding of the PH domain to the membrane. This work is well written. The figures are very clear and easy to understand. The data are presented in logic orders.
Specific comments: 1. Title: Tiam1 PHCCEx as 'peptide-binding module¥ is misleading and very general. The peptides studied in this work are part of distinct proteins. 'Peptide¥ should be changed to 'protein¥.
2. Abstract: What are 'target proteins¥? Tiam1 itself is most likely the target protein in the case of CD44 and Ephrin B. The last sentence is not correct in this case! 3. Page 12: Figure S6 and its description are unclear. Should bind Tiam1? One expects a much better quality for a high affinity interaction. In addition, it seems that there is a mistake in 'the acidic cluster region (residues 931-950 919-948)¥. 4. Page 13: Data for mutational analysis of Lys650, Lys653 and Arg691 are not shown. It is important to show at least one negative control in Figure 8B . 5. Tiam1 has been shown to interact also with the NMDA-type glutamate receptor and thereby it controls the growth and morphology of dendritic spines. Did the authors analyze this type of receptors for an acidic motif? 6. Small GTPase Ran has got an acidic C-terminal tail! Does this peptide share some homology to Acidic peptide analyzed in this study? This may be interesting because Tiam1 has been reported to play some roles in the nucleus. Figures 3 and 6B seem dispensable. Figure 3 shows a high identity of Tiam1/2 in mouse, human and fly. Critical information in Figure 6B is Par3 sequence that is shown in 6A. Questions of how Tiam1 is integrated in different signalling pathways at the membrane, how its interaction with different signalling molecules is determined (e.g. in a cell type-or tissue-dependent manner?) could be discussed better.
The alignments in
Referee #2 (Remarks to the Author):
Tiam1 and Tiam2 are closely related members of the Dbl-family GEFs for Rac1. Insights into the mechanism of action for these proteins are important to further our understanding of cytoskeletal reorganization underlying both cell motility and the establishment of cell polarity. The authors report a crystallographic structure of the PH-CC-Ex regions of Tiam2 and Tiam1. This structured domain serves an essential role in membrane localization of Tiam1 and the subsequent activation of Rac1. PH-CC-Ex is believed to accomplish this task through direct interactions with phosphoinositides and other proteins including CD44, ephrin B1, Eph B2, JIP-1, JIP-2, spinophillin and Par3. The authors subsequently identify a putative site of protein interaction on Tiam1/2 through mutagenesis and peptide binding studies. Overall, the structural findings suggest how the integrated PH-CC-Ex subdomains may coordinate phosphoinostide and protein interactions. While this is interesting, many of the structure-function observations based on their mutagenesis and peptide binding analysis would be vastly strengthened with further validation. For example, the peptidebased findings could be extended to investigate the effects of their Tiam1/2 mutants on proteinprotein interactions by co-immunoprecipitation experiments and/or Rac1 functional assays. As a result, in my view, the current version of this manuscript is not suitable for publication in EMBO J. What follows is a more detailed analysis of the manuscript and specific recommendations for some further experiments. 1) Page 7. Comparison of the Tiam PH domain fold with other similar structures (PTB, EVH, PHear) is followed by an unsupported conclusion that peptide-binding ability is not specifically conferred by the PH subdomain of PHCCEx. No mutagenesis data on the PTB interacting region ( 5-1 elements) of Tiam2 PH domain is provided to demonstrate this point. I would recommend use of stereo-figures to improve the usefulness of Figures such as 2A, 2D and 4B,C,D.
2) Tiam2/Peptide binding studies performed by SPR with Biotin-labelled peptide on chip. Affinities for the binding reactions are between 0.1-5.0 micromolar. There is no control provided for specificity of the observed interactions (beyond a general electrostatic effect) such as investigating a scrambled version of their peptide sequences. Point mutations of the conserved acidic residues in the CD44 and ephrin class (see Fig 5C,6A) would also strengthen the validity of these observed interactions as well.
3) A total of eight alanine mutants were generated within Tiam2, five within the conserved basic patch that exhibited reduced binding to the CD44 peptide while three distal sites on the CC domain demonstrated no reduction in peptide binding. Tiam1/2 is proposed to bind phosphoinostides and protein targets simultaneously given the proximity of the basic interactions sites. This point has not been addressed since mutations within the PIP binding pocket were not assessed for effects on peptide interactions and the described peptide-binding site mutants were not assessed for potential effects on PIP interactions. 4) An obvious and key question would be "what is the role of Tiam1/2 interaction with CD44, Par3 and others within cells?" With a potentially interesting set of Tiam1/2 mutants, the authors can address if their identified peptide interaction site is relevant to the protein interactions within cells by co-immunoprecipitation experiments and effects on Rac1 activation by PAK-pulldown assays. Disruption of Tiam1-mediated protein-protein interactions and their consequences on Rac1 activation could shed light on the importance of Tiam1/2 specific cellular localization for polarity or migration functions. 5) Some tempting speculations are also raised in the discussion. First, due to the non-overlapping region of the CD44 cytoplasmic tail that binds ERM proteins and TIAM1/2, are these proteins suggested to bind CD44 independently or simultaneously? 6) Interpretation of a Tiam1 missense mutation (A441G) with respect to a role in enhancing phosphoinositide interaction is pure speculation and unsupported. Major points:
The analysis of the interaction between the Tiam fragment and peptides of several Tiam interacting proteins requires some clarification. Several peptides of CD44 are used to map the interacting area with the Tiam fragment by SPR. A semi quantitative score (-, + and ++) for the ability of the peptides to interact with Tiam is given in figure 5A . The titration curves for selected peptides are shown in figure 5B . (i) The data for all peptide should be show.
(ii) A logarithmic scale should be chosen for the x-axis of figure 5B. Only a logarithmic plot allows to judge whether saturation was reach in course of the titration. (iii) Interestingly peptide 314-343 is scored with + in figure 5A . However, the fitted curve in figure  5B shows a very similar shape as those for the peptides 327-350 and 334-363, which are scored ++. The difference between the peptides seems not to be the affinity (shape of the curve) but the intensity of the signal that is achieved under saturating conditions (which is given despite others by the density of the immobilised peptides). The authors should comment on this.
(iv) Affinities should be determined for the Tiam mutants presented in Figure 8B by carrying out a full titration rather than the used of a single concentration only. The absolute value obtained for a single concentration is only partially reflecting the affinity (see also (iii)). The clarity of the structural figures could be improved. For example the Ins(1,4,5)P3 is hardly visible in figure 2D . In general a lot of spotlight/shadow and colour gradient effects are applied to the structural figures. The figures might gain clarity if these effects are reduced. For example some elements of figures 2A and B are appearing so light that it is difficult to trace the fold. Similar, in figures 4 B-D it is sometimes difficult to connect the individual amino acid to the backbone trace.
Minor comments:
Figure 3: The sequence of "Tiam1 human" is missing in the last row. The colour code (colour in which the letters are printed) should be defined or colours should be removed. Figure 5C : What is the definition of "invariant amino acids"? The used definition considers for example N=H or S=N=K. Figure 5C is analysing a consensus sequence for protein interaction. In this context it might be questionable whether for example a lysine can substitute for a serine. Thus the authors might want to apply are more strict conservation criterion for highlighting amino acids. The colour code used for the letters should be defined. We changed peptide to protein (page 1).
>2. Abstract: What are 'target proteins'? Tiam1 itself is most likely the target protein in the case of CD44 and Ephrin B. The last sentence is not correct in this case!
'target' was deleted from Abstract (page 1). Figure S6 and its description are unclear. Should We believe that GST-Par3 (919-928) should read GST-Par3 (919-1028), which is shown in Figure S6 . Yes, GST-Par3 (919-1028) binds Tiam1 as well as Tiam2. In our study, the Tiam1 PHCCEx domain binds all the peptides that were found to bind the Tiam2 PHCCEx domain.
>3. Page 12:
We correct the mistake in the text with the acidic cluster region (919-948) (page 12, bottom). Figure S6 may be somewhat weaker than expected. We believe that this is because the interaction between Par3 and Tiam1 is largely electrostatic and the exchange velocity, i.e. the dissociation/association velocities, seems to be high at our experimental condition (150 mM NaCl). At a lower salt concentration (50 mM NaCl), we observed stronger shifted bands, but we also observed some bands caused by non-specific binding. Therefore, we decided to leave the figure as it was.
Shifted bands in
The longer fragment, Par3(919-1028), contains both the N-terminal acidic cluster and the C-terminal basic region. We speculate that the C-terminal basic region may interfere with the acidic cluster binding to Tiam1/2 by making electrostatic interacts with the acidic cluster. For the present, we think that this is an artificial interaction. However, it may occur in the full-length Tiam1/2. This is another interesting issue to be addressed in future. Figure 8B .
>4. Page 13: Data for mutational analysis of Lys650, Lys653 and Arg691 are not shown. It is important to show at least one negative control in
As suggested, we added the sensor gram of Lys650 as a representative of the negative mutations in Figure 8B . The others (Lys653 and Arg691), which are heavily overlapped with those of the wild-type and Lys650, were omitted for clarity.
>5. Tiam1 has been shown to interact also with the NMDA-type glutamate receptor and thereby it controls the growth and morphology of dendritic spines. Did the authors analyze this type of receptors for an acidic motif?
This is an interesting point in the Tiam1/2 study. Yes, we once had investigated the sequence of the NMDA-type glutamate receptor (NMDAR and found two candidates for bindingregions in the NR1 subunit that was previously shown to bind Tiam1: One is found within the cytoplasmic loop I, which is located between transmembrane helices 1 and 2, and the other in the cytoplasmic C-terminal tail. At this time, we prepared the NMDAR peptides for binding assay. We found that the PHCCEx domain indeed binds the NMDR loop I peptide with a comparable affinity (KD of 0.17 M) with those for acidic clusters of Par3 and JIP2, but does not bind the C-terminal tail peptide. We mentioned this in the text (page 12, upper paragraph) with description of additional experiments (page 22) and one reference, Tolias et al., Neuron 2005 (page 29).
>6. Small GTPase Ran has got an acidic C-terminal tail! Does this peptide share some homology to Acidic peptide analyzed in this study? This may be interesting because Tiam1 has been reported to play some roles in the nucleus.
This is another interesting question. Indeed, the Ran C-terminal sequence contains an acidic cluster (-GDPEDDDL) that displays some homology to our acidic motif or acidic cluster. Using a biotinylated Ran C-terminal tail peptide, we performed binding assay by SPR measurements and detected signals, which suggest binding to the C-terminal tail. We mentioned this issue briefly in Discussion (page 17, upper paragraph).
>7. The alignments in Figures 3 and 6B seem dispensable. Figure 3 shows a high identity of Tiam1/2 in mouse, human and fly. Critical information in Figure 6B is Par3 sequence that is shown in 6A. Questions of how Tiam1 is integrated in different signalling pathways at the membrane, how its interaction with different signalling molecules is determined (e.g. in a cell type-or tissuedependent manner?) could be discussed better.
As suggested, we moved Figure 6B to Supplementary Figure S6A . We kept Figure 3 as it was since the PHCCEx domain is a really novel one and we believe that the sequences with the secondary structure elements could help readers understanding.
We tried to discuss Tiam1 integration in different signalling pathways in Discussion section with a new paragraph (page 18).
Referee #2: >While this is interesting, many of the structure-function observations based on their mutagenesis and peptide binding analysis would be vastly strengthened with further validation. For example, the peptide-based findings could be extended to investigate the effects of their Tiam1/2 mutants on protein-protein interactions by co-immunoprecipitation experiments and/or Rac1 functional assays. As a result, in my view, the current version of this manuscript is not suitable for publication in EMBO J. What follows is a more detailed analysis of the manuscript and specific recommendations for some further experiments.
We performed co-immunoprecipitation and lamellipodia formation experiments and confirmed the importance of the protein-protein interactions in cells as described below.
>1) Page 7. Comparison of the Tiam PH domain fold with other similar structures (PTB, EVH, PHear) is followed by an unsupported conclusion that peptide-binding ability is not specifically conferred by the PH subdomain of PHCCEx. No mutagenesis data on the PTB interacting region (beta-5, alpha-1 elements) of Tiam2 PH domain is provided to demonstrate this point. I would recommend use of stereo-figures to improve the usefulness of Figures such as 2A, 2D and 4B, C, D.
We regret that our poor description was cause for referee's concern about possibility of peptide-binding to the PH subdomain. We should have mentioned first the fact that the groove between beta-5 strand and alpha-1 helix of our PH subdomain is completely covered by CC and Ex subdomains. Therefore, the PHCCEx domain does not permit for peptides to access the groove of the PH subdomain. We mentioned this in the text (page 7, middle). In addition, our carful structural comparison enables to distinguish PH and PTB domains since PTB domains possess a wide groove between beta-5 strand and alpha-1 helix for peptide binding, whereas PH domains possess a narrower groove by ~2 Å. Our PH subdomain possesses this too narrow groove to bind a peptide chain. Indeed, the isolated Tiam1 PH subdomain exhibited no binding activity to our peptides (data not shown). Thus, all our structural comparison and inspection suggests no such peptide-binding ability of our PH subdomain.
As suggested, stereo views of Figures 2A, 2D and 4B-D were prepared. Fig 5C,6A) would also strengthen the validity of these observed interactions as well.
>2)

Tiam2/Peptide binding studies performed by SPR with Biotin-labelled peptide on chip. Affinities for the binding reactions are between 0.1-5.0 micromolar. There is no control provided for specificity of the observed interactions (beyond a general electrostatic effect) such as investigating a scrambled version of their peptide sequences. Point mutations of the conserved acidic residues in the CD44 and ephrin class (see
As suggested by the referee, we decided to perform additional binding assay with mutated CD44 peptides to strengthen the validity of our observed interactions. The results are summarized in Figure 6B . We found that two glutamates of the EPSE sequence are critical for binding to the Tiam2 PHCCEx domain but also Cys345 of the CMTAD sequence is very important. At this mouse Cys position, ephrin Bs conserve a Leu residue and CD44s from human and other most of mammalians conserve a Phe residue. Thus, the Cys position should be a hydrophobic residue, which contributes to binding affinity by nonpolar interactions with the PHCCEx domain. Furthermore, we noticed that this hydrophobic residue is conserved in Par3. We mentioned the results in the text (page 11 bottom). We had known that hydrophobic residues are conserved in this Cys position, but we never realized that this is a key position important for binding. We wish to thank the referee for pushing us to this additional experiment.
>3) A total of eight alanine mutants were generated within Tiam2, five within the conserved basic patch that exhibited reduced binding to the CD44 peptide while three distal sites on the CC domain demonstrated no reduction in peptide binding. Tiam1/2 is proposed to bind phosphoinostides and protein targets simultaneously given the proximity of the basic interactions sites. This point has not been addressed since mutations within the PIP binding pocket were not assessed for effects on peptide interactions and the described peptide-binding site mutants were not assessed for potential effects on PIP interactions.
We performed PIP-binding assay with the mutant PHCCEx domains by a fluorescence polarization-based assay using a fluorescent moiety-labeled PIP3 analog and compared the obtained affinities (Supplementary Figure S9A) . We observed no significant changes in the PIP3-affinity for any mutant Tiam2 PHCCEx domain (R716A, R693A or K632A) that significantly decreases CD44 binding. We also performed CD44-, Par3-and ephrin B1-binding assays in the presence of PIP3 (Supplementary Figure S9C) . We found that PIP3-binding does not significantly affect on these peptide bindings. Furthermore, we performed PIP3 binding assay in the presence or absence of the CD44, Par3 or ephrin B1 peptides (Supplementary Figure S9D) . We confirmed that neither of these peptides virtually affected on PIP3 binding to the PHCCEx domain.
All these experiments suggest that PIs-and peptide-bindings are basically independent. These results are described in the text (page 14 bottom).
>4) An obvious and key question would be "what is the role of Tiam1/2 interaction with CD44, Par3 and others within cells?" With a potentially interesting set of Tiam1/2 mutants, the authors can address if their identified peptide interaction site is relevant to the protein interactions within cells by co-immunoprecipitation experiments and effects on Rac1 activation by PAK-pulldown assays. Disruption of Tiam1-mediated protein-protein interactions and their consequences on Rac1
activation could shed light on the importance of Tiam1/2 specific cellular localization for polarity or migration functions.
As suggested, we investigated in vivo interactions with co-immunoprecipitation with mutated Tiam1 PHCCEx domains. We used COS7 cells transfected with the plasmids for GFPTiam1 and HA-Par3. We found that Par3 is well co-immunoprecipitated with the wild type Tiam1, but co-immunoprecipitation is clearly reduced in the case of the mutant Tiam1 (R622A and R645A), which corresponds to the mutant Tiam2 (R693A, R716A). Results are shown in Figure 9A and discussed (page 14 bottom -15).
Moreover, we investigated lamellipodia induction by Par3-activated Tiam1. The N4/1 fragment of Par3 was known to induce lamellipodia by Taim1-mediated Rac1 activation (Nishimura et al., in Nat Cell Biol 2005) . This effect was inhibited by the isolated PHCCEx domain that was known to play as a dominant-negative factor that interferes with Par-3-Tiam1 binding (Matsuo et al., 2002; Nishimura et al., 2005) . We observed this dominant-negative effect by the wild-type and mutant Tiam1 PHCCEx domains and found that mutations (R622A, R645A and their double mutation) at the peptide-binding sites of the PHCCEx domain markedly decrease the inhibitory effect compared with the wild-type ( Figure 9B ).
In conclusion, all our data strongly suggested that the peptide-binding site that we found is critical for Tiam1 activation in cells.
>5) Some tempting speculations are also raised in the discussion. First, due to the nonoverlapping region of the CD44 cytoplasmic tail that binds ERM proteins and TIAM1/2, are these proteins suggested to bind CD44 independently or simultaneously?
As we discussed in the discussion, the CD44 cytoplasmic tail exists as a flexible random coil with two binding sites located at very distant positions (~30 residues apart), we think that CD44 is able to bind both ERM proteins and Tiam1 simultaneously, whereas two bindings are mutually independent with no interference. To prove the ternary (Tiam1-CD44-ERM) complex formation, we performed a binding assay using SPR measurements, which showed that ERM proteins (radixin) bind Tiam2-immobilized sensor chip in the presence of CD44 (Supplementary Figure S11) , suggesting that CD44 mediates radixin binding to Tiam1-coated sensor chip by binding to both proteins. Thus, the ternary complex could be formed (page 18, top).
>6)
Interpretation of a Tiam1 missense mutation (A441G) with respect to a role in enhancing phosphoinositide interaction is pure speculation and unsupported.
We modified our speculation based on our additional PIP-binding assay (Supplementary Figure S9B) , which showed only a small change in binding affinity by the missence-mutation (page 19 middle). (-, + and ++) for the ability of the peptides to interact with Tiam is given in figure 5A . The titration curves for selected peptides are shown in figure 5B . As suggested, Figure 5B was improved with logarithmic plots and all data for bound peptides were shown. The semi-quantitative scores were revised based on the plots ( Figure 5A ). figure 5A . However, the fitted curve in figure  5B shows a very similar shape as those for the peptides 327-350 and 334-363, which are scored ++. The difference between the peptides seems not to be the affinity (shape of the curve) but the intensity of the signal that is achieved under saturating conditions (which is given despite others by the density of the immobilised peptides). The authors should comment on this.
>(iii) Interestingly peptide 314-343 is scored with + in
Because the obtained SPR resonances were normalized with the quantity of immobilized peptides, we can compare SPR resonances from sensor chips that are immobilized with different peptides. Therefore, the intensity of the resonance signals in the figure would reflect the affinity to some extent. In the revised version, we and presented much more reliable semi-quantitative scores based on the improved logarithmic plots (see our responses to point (ii)). Figure 8B by carrying out a full titration rather than the used of a single concentration only. The absolute value obtained for a single concentration is only partially reflecting the affinity (see also (iii)).
>(iv) Affinities should be determined for the Tiam mutants presented in
At this stage, we know the dissociation constant of the wild-type PHCCEx domain binding to the CD44 peptide. Therefore, we set the PHCCEx concentration to 1.0 microM that is close to the dissociation constant (0.92 microM), which is, physico-chemically, the most sensitive concentration for detection of mutational effects. Therefore, our experimental design is optimal for our purpose, mapping the CD44-binding surface on our 3D structure but not gleaning quantitative effects of mutations. For reference, we performed a quantitative binding assay with selected mutations that significantly affected on peptide binding ( Figure 8B ). Mutations corresponding to these mutations were successively used in vivo experiments (see Figure 9 and our responses to point-4 of referee#2). The single (R716A) and double (R716A and R693A) mutations decrease the CD44-binding affinity to ~20% and 4% of that for the wild-type, respectively, in terms of dissociation constant values.
We are planning our fully quantitative analyses of mutations when we obtained the threedimensional structures of the PHCCEx-CD44 and/or PHCCEx-Par3 complex(es). Knowledge of quantitative changes in the affinity by each mutation is useful for obtaining further structural insight in the context of the three-dimensional complex structures, but not for obtaining our major insight without any complex structure. We presented the Par3 data in Supplementary Figure S8 , which clearly shows mutational effects similar to those on CD44 binding.
>(v) Par3 interacts with a similar region in Tiam as
>(vi) If technically possible the author might want to make use of single point mutations in the CD44 and Par3 peptides to further define the consensus motif for recognition by Tiam.
Preserving the common acidic motif, the CD44, ephrin Bs and NMDAR peptides are expected to bind the PHCCEx domain in a similar manner and form essentially the same conformation on binding. The Par3 and JIP2 peptides, however, bind the PHCCEx domain in a manner that may differ from that of CD44 and the related peptides. We speculate that, on PHCCEx binding, the Par3 and JIP2 peptides form somewhat different conformations from those of the CD44, ephrin Bs and NMDAR peptides. Therefore, we think that it is quite difficult to define a single consensus motif without 3D structures of the Tiam-CD44 and Tiam-Par3 complexes.
We feel that we are better to concentrate to determine the complex structures first, rather than to dare to perform several mutational and binding studies. Instead, we performed mutational analysis of the CD44 peptide to further define important residues of the acidic motif found in CD44 and ephrin Bs ( Figure 6B ) (see our responses to point 2 by the referee#2). This mutational analysis implied that Par3 preserves some key residues found in the acidic motif. We speculated that Par3 binding may have some common characteristics with those of CD44 and its related proteins. Contrary to the similarity between the Par3 acidic cluster and the CD44 acidic motif, the JIP2 acidic cluster is quite distinct from the CD44 acidic motif and may display a different binding manner from that of the CD44 acidic cluster, while both bind a similar region on the PHCCEx domain. figure 6A ?
>(vii) The
We performed SPR measurements with Tiam1 PHCCEx domain and results were added in Figure 6A . Overall, no significant differences in preferences for the peptides are observed between Tiam1 and Tiam2, although Tiam1 binding is somewhat weaker than that of Tiam2. We speculate that this is probably because of small differences in the electrostatic distribution of the binding surfaces. At present, we are unable to define residues that induce the observed differences in the binding affinity since we have only a low-resolution structure of the Tiam1 PHCCEx domain. We mentioned this briefly in the text (page 11, the second paragraph). We reduced the effects of spotlighting/shadowing and prepared stereo views of the molecule for convenience (Fig. 2B, 2D , 4B-D).
Minor comments:
>Figure 3: The sequence of "Tiam1 human" is missing in the last row. The colour code (colour in which the letters are printed) should be defined or colours should be removed.
We improved the figure and its legend to clarify the definition. Figure 5C is analysing a consensus sequence for protein interaction. In this context it might be questionable whether for example a lysine can substitute for a serine. Thus the authors might want to apply are more strict conservation criterion for highlighting amino acids. The colour code used for the letters should be defined.
We revised Fig. 5C and clarified the definition of invariant amino acids and the color codes. As suggested by the referee, we modified the definition to be stricter. Thank you for submitting your revised manuscript for our consideration. It has now been seen once more by the original referees 2 and 3, and I am pleased to inform you that both of them consider your study significantly improved and would therefore in principle now support publication in The EMBO Journal. There remain, however, a few issues connected to the new data added in Figure 9a in response to the original reviewer comments. On one hand, referee 2 asks for both a better description of this experiment in the figure legend, as well as for a negative control for the depicted co-immunoprecipitation. On the other hand, we noted in the same figure panel signs of apparent
